HU9602750D0 - Treatment of autoimmune disease using oral tolerization and/or type i interferon - Google Patents

Treatment of autoimmune disease using oral tolerization and/or type i interferon

Info

Publication number
HU9602750D0
HU9602750D0 HU9602750A HU9602750A HU9602750D0 HU 9602750 D0 HU9602750 D0 HU 9602750D0 HU 9602750 A HU9602750 A HU 9602750A HU 9602750 A HU9602750 A HU 9602750A HU 9602750 D0 HU9602750 D0 HU 9602750D0
Authority
HU
Hungary
Prior art keywords
interferon
treatment
type
autoimmune disease
oral tolerization
Prior art date
Application number
HU9602750A
Other languages
Hungarian (hu)
Other versions
HUT74900A (en
Inventor
David A Hafler
Howard L Weiner
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of HU9602750D0 publication Critical patent/HU9602750D0/en
Publication of HUT74900A publication Critical patent/HUT74900A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
HU9602750A 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon HUT74900A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08

Publications (2)

Publication Number Publication Date
HU9602750D0 true HU9602750D0 (en) 1996-11-28
HUT74900A HUT74900A (en) 1997-02-28

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602750A HUT74900A (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Country Status (9)

Country Link
EP (1) EP0752880A4 (en)
JP (1) JPH09511745A (en)
AU (1) AU686797B2 (en)
BR (1) BR9507451A (en)
CA (1) CA2185353A1 (en)
HU (1) HUT74900A (en)
IL (1) IL113303A0 (en)
NO (1) NO964199D0 (en)
WO (1) WO1995027499A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
SI9520118A (en) * 1994-10-25 1998-08-31 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
TR199901968T2 (en) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit sabit interferon formlleri
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
CA2284271C (en) 1997-03-21 2012-05-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU6481301A (en) 2000-05-24 2001-12-03 Us Health Methods for preventing strokes by inducing tolerance to e-selectin
CA2511209A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Agent for treatment of pemphigoid
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (en) * 2013-11-11 2019-10-16 キッコーマン株式会社 Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
BR9306042A (en) * 1992-02-28 1997-11-18 Autoimmune Inc Method to treat an autoimmune disease in a mammal and oral and inhalable pharmaceutical dosage forms

Also Published As

Publication number Publication date
EP0752880A1 (en) 1997-01-15
BR9507451A (en) 1997-08-05
NO964199L (en) 1996-10-03
EP0752880A4 (en) 2000-08-09
AU2277695A (en) 1995-10-30
IL113303A0 (en) 1995-07-31
NO964199D0 (en) 1996-10-03
JPH09511745A (en) 1997-11-25
AU686797B2 (en) 1998-02-12
WO1995027499A1 (en) 1995-10-19
CA2185353A1 (en) 1995-10-19
HUT74900A (en) 1997-02-28

Similar Documents

Publication Publication Date Title
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
HK44797A (en) Treatment of conditions and disease
PL312718A1 (en) Competitors and opponents of human interleukine-10
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
HU9602750D0 (en) Treatment of autoimmune disease using oral tolerization and/or type i interferon
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
EP1030663A4 (en) Treatment of fibromyalgia and related disorders
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
HUP0003244A2 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
HUP9800829A3 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
GB9419571D0 (en) Treatment of oral infections
PL322002A1 (en) Variants of human dnase i
GB9611500D0 (en) Prevention and treatment of oral conditions with peptides having anti-adherence activity
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
EP0833641A4 (en) Treatment and prevention of prostatic disease
EP0540575A4 (en) Human meg-csf protein and methods
GB9516572D0 (en) Prevention and/or treatment of disease
NZ277605A (en) Human stanniocalcin-alpha polypeptide and dna (rna) encoding polypeptide; polypeptide may be derived from atcc 75861
IL115017A0 (en) Methods of maintaining teeth and oral bone
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
EG20171A (en) Treatment of conditions and disease
ZA951440B (en) Novel opiold peptides for the treatment of pain and use thereof
PL342649A1 (en) Prevention of amyloidogenous diseases and treatment of them
HU9400634D0 (en) Vaccine and diagnosticum against parvovirosis of gooses and barbari duks

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee
DNF4 Restoration of lapsed final protection
DFD9 Temporary protection cancelled due to non-payment of fee